🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
During Phase 1b portion, there will be a dose-escalation of AV-299 (formerl...
Status
Completed
Location
Investigational Site 1
Start Date
2009-12
Trial ID
NCT01039948
Treatments Being Tested
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer ari...
Status
Terminated
Location
UPMC Presbyterian
Start Date
2015-09
Trial ID
NCT02277184
Treatments Being Tested
This is a Phase 2, randomized, open-label, multicenter study to evaluate th...
Status
Withdrawn
Location
Multiple Locations
Start Date
2020-01-31
Trial ID
NCT04100330
Treatments Being Tested
The purpose of this study is to compare the efficacy and safety of ficlatuz...
Status
Recruiting
Location
Banner MD Anderson Cancer Center
Start Date
2024-01-11
Trial ID
NCT06064877
Treatments Being Tested
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pha...
Status
Completed
Location
Investigational Site 1
Start Date
2009-08
Trial ID
NCT00969410
Treatments Being Tested
This randomized phase II trial studies how well ficlatuzumab with or withou...
Status
Completed
Location
The University of Arizona Cancer Center
Start Date
2017-12-05
Trial ID
NCT03422536
Treatments Being Tested
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient...
Status
No Longer Available
Location
START
Start Date
TBD
Trial ID
NCT02090127
Treatments Being Tested
To identify the maximally tolerated dose of ficlatuzumab when combined with...
Status
Completed
Location
Massachusetts General Hospital
Start Date
2018-01-17
Trial ID
NCT03316599
Treatments Being Tested
The epidermal growth factor receptor (EGFR) is both oncogene and prognostic...
Status
Completed
Location
UPMC Presbyterian
Start Date
2015-08
Trial ID
NCT02277197
Treatments Being Tested
Phase 1 study to determine safety, tolerability, dose-limiting toxicities (...
Status
Completed
Location
Investigational Site 2
Start Date
2008-09
Trial ID
NCT00725634
Treatments Being Tested